Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)

泰国艾滋病毒/艾滋病和传染病临床试验单位（THAI CTU） SF 424（R&R）其他项目信息-项目摘要 泰国艾滋病毒/艾滋病和传染病临床试验单位（THAI CTU），目前NIAID CRM网站 60338，是清迈大学健康科学研究所（CMU- 泰国清迈的RIHES）和曼谷的泰国红十字会艾滋病研究中心（TRC-ARC）， 泰国本申请的具体目的是：1）将泰国CTU更新为临床试验单位， 科学，管理专业知识和基础设施，以进行由四个NIH开发的临床研究 艾滋病毒/艾滋病临床试验网络：艾滋病毒/艾滋病成人治疗，艾滋病毒/艾滋病孕产妇，青少年和儿科 治疗，艾滋病毒预防和艾滋病毒疫苗; 2）参与临床试验的开发， 提供四个临床研究中心（CRS），以开展四个网络提议的临床试验。这个反恐小组 更新涉及泰国CTU首席调查员的变更，即“Suwat Chariyalertsak和Kiat Ruxrungtham”改为“Khuanchai Supparatpinyo and Kiat Ruxrungtham”。泰国反恐组和它的四个CRS将 为网络做出科学贡献，并根据以下标准招募艾滋病毒阳性和艾滋病毒阴性参与者参加临床研究： 艾滋病毒/艾滋病研究优先事项： 1)艾滋病毒/艾滋病成人治疗：1）减少艾滋病毒储存库的干预措施; 2）新颖和持久 针对艾滋病毒治疗的干预措施; 3）治疗和预防对药物敏感和耐药的 结核病; 4）治疗和预防艾滋病毒相关的非传染性共病; 5）研究 治疗感染和未感染艾滋病毒的人的B型肝炎病毒感染的策略。全国高发病率 病毒性肝炎和携带的地方性促进了对HBV和HCV感染的研究， 用于治疗B型肝炎。 2)艾滋病毒/艾滋病孕产妇、青少年和儿科治疗：1）优化抗逆转录病毒治疗 2）无ART缓解的干预措施; 3） 结核病; 4）治疗和预防艾滋病毒相关的并发症; 5）治疗和 预防合并感染。 3)艾滋病毒预防：1）评价长效抗逆转录病毒药物和用于预防艾滋病毒感染的输送系统; 暴露预防; 2）评估艾滋病毒、妊娠、 性传播感染和阿片类药物依赖; 3）评价广泛中和抗体 暴露前预防;和4）艾滋病毒预防的综合战略。 4)艾滋病毒疫苗：1）评估被动免疫以减少成人感染艾滋病毒; 2） 婴儿疫苗接种调查; 3）免疫学、微生物学和诊断学评价 结核病疫苗接种技术; 4）流行病学、行为学和社会科学研究 优化艾滋病毒疫苗接种的效果。

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) SF 424 (R&R) Other Project Information – Project Summary The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU), current NIAID CRMS site 60338, is a collaboration between the Chiang Mai University-Research Institute for Health Sciences (CMU- RIHES) in Chiang Mai, Thailand, and the Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, Thailand. The specific aims of this application are 1) to renew the THAI CTU as a Clinical Trials Unit to provide scientific, administrative expertise, and infrastructure to conduct clinical studies developed by the four NIH HIV/AIDS Clinical Trials Networks: HIV/AIDS Adult Therapeutics, HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics, HIV Prevention, and HIV Vaccines; and 2) to participate in the development of clinical trials and provide four Clinical Research Sites (CRS) to conduct clinical trials proposed by the four Networks. This CTU renewal involves a change of THAI CTU Principal Investigators from "Suwat Chariyalertsak and Kiat Ruxrungtham" to “Khuanchai Supparatpinyo and Kiat Ruxrungtham". The THAI CTU and its four CRSs will contribute scientifically to the Networks and recruit HIV+ and HIV- participants to clinical studies according to HIV/AIDS research priorities: 1) HIV/AIDS adult therapeutics: 1) interventions to reduce HIV reservoirs; 2) novel and durable interventions targeting HIV treatment; 3) treatment and prevention of drug-sensitive and drug-resistant tuberculosis; 4) treatment and prevention of HIV-related, non-infectious co-morbidities; and 5) studied strategies to cure hepatitis B virus infection in people with and without HIV. High national incidence of viral hepatitis and endemicity of carriage facilitates research on HBV and HCV infections, particularly for cure of hepatitis B. 2) HIV/AIDS maternal, adolescent and pediatric therapeutics: 1) optimization of antiretroviral treatment for these populations; 2) interventions for ART-free remission; 3) treatment and prevention of tuberculosis; 4) treatment and prevention of HIV-related co-morbidities; and 5) treatment and prevention of co-infections. 3) HIV prevention: 1) evaluation of long-acting antiretroviral agents and delivery systems for pre- exposure prophylaxis; 2) evaluation of multipurpose prevention technologies for HIV, pregnancy, sexually transmitted infections, and opioid dependence; 3) evaluation of broadly neutralizing antibodies for pre-exposure prophylaxis; and 4) integrated strategies for HIV prevention. 4) HIV vaccines: 1) evaluation of passive immunization to reduce HIV acquisition in adults; 2) investigation of vaccination of infants; 3) evaluation of immunological, microbiological, and diagnostic technologies for TB vaccination; and 4) research on epidemiological, behavioral, and social sciences for optimization of outcomes of HIV vaccination.